AUTHORS
Qiang WANG, MD, Li Weiming, MD2, Xin Du, MD3, Xiaotao Wang4, Liling Zheng5, Bingbing Wen6, Xuan Zhou, PhD7, Changxin Yin8, Yan Zhang9, Zechen Miao10, Zhengzheng Fu11, Qifa Liu, MD12, Xiaoli Liu, MD13, Na Xu14
AFFILIATIONS
1 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 The Second People's Hospital of Shenzhen, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
4 The First Affiliated Hospital of Guilin Medical University, Guilin, China
5 The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, China
6 The Second People's Hospital of Shenzhen, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
7 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
8 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
9 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
10 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
11 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
12 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
13 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
14 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
ABSTRACT
Introduction
Flumatinib is a second-generation BCR::ABL1 tyrosine kinase inhibitor (TKI) approved for the treatment of chronic-phase chronic myeloid leukemia (CML-CP). Although increases in serum creatinine (Cr) have been documented during TKI therapy, their clinical significance and association with molecular response in the context of first-line flumatinib remain inadequately characterized. This prospective study evaluated molecular response outcomes and investigated whether changes in Cr levels during treatment correlate with dose intensity or the magnitude of BCR::ABL1 reduction in patients with newly diagnosed CML-CP.
Methods
This prospective, multicenter, real-world study enrolled 480 adults with newly diagnosed CML-CP who received first-line flumatinib across centers in China between May 2020 and June 2024(NCT04591197). Dose information was available for 451 patients on stable dosing regimens: 415 received 600 mg once daily, and 36 received 400 mg once daily due to intolerance or baseline comorbidities. Major molecular response (MMR), MR4.0, and MR4.5 were defined as BCR::ABL1 transcript levels ≤0.1%, ≤0.01%, and ≤0.0032% on the International Scale (IS), respectively. Serum Cr was assessed serially throughout treatment. The relationship between BCR::ABL1 reduction and changes in Cr was evaluated using Pearson correlation analysis; Annualized Cr change was calculated for patients with ≥24 months of follow-up. Changes in Cr from baseline are expressed as percentage change: (time-point mean − baseline mean) / baseline mean × 100.
Results
The median age was 40 years (range, 18–80), 62.3% of patients were male, and the median follow-up was 27 months (range, 15–42). Baseline estimated glomerular filtration rate was comparable between the 600 mg and 400 mg groups (95.7 ± 21.6 vs. 92.8 ± 18.4 mL/min/1.73 m²). In the 600 mg group, the MMR rate rose from 36.3% at 3 months to 73.3% at 12 months and 80.8% at 24 months. MR4 and MR4.5 rates at 12 months were 43.6% and 33.5%, respectively; at 24 months, they were 50.0% and 40.4%. In the 400 mg group, 12-month MMR and MR4 rates were 70.0% and 40.0%, respectively, with a higher rate of second-line therapy switching compared with the 600 mg group (19.4% vs. 11.1%). Mean Cr in the 600 mg group increased from 78.6 ± 22.6 μmol/L at baseline to 88.7 ± 32.8 μmol/L at 12 months (+12.8%) and subsequently stabilized at 86.5 ± 22.1 μmol/L at 24 months (+10.0%). In the 400 mg group, Cr increased from 79.6 ± 15.6 to 85.5 ± 14.1 μmol/L at 12 months (+7.3%). Cr changes did not differ significantly between two dose groups at 3 months (+10.5% vs. +1.2%; P = 0.61) or 12 months (+12.4% vs. +6.8%; P = 0.52). Among 122 patients with ≥24 months of follow-up, 72.1% maintained stable renal function (annualized Cr change within ±5 μmol/L/year), and 1.6% experienced Cr doubling from baseline. BCR::ABL1 transcript levels did not demonstrate a consistent correlation with concurrent Cr changes at any time point (3 months: r = 0.158; 6 months: r = −0.078; 9 months: r = −0.099; 12 months: r = 0.212; 18 months: r = 0.056; 24 months: r = 0.276). Furthermore, log reduction in BCR::ABL1 from baseline to 12 months showed a negligible correlation with Cr changes (r = 0.066, n = 91). Cr changes were comparable between patients who achieved MMR and those who did not at 3 months (+2.7% vs. +6.0%; P = 0.56) and 6 months (+6.9% vs. +10.1%; P = 0.50).
Conclusion
This prospective multicenter real-world cohort study of 451 patients demonstrates that first-line flumatinib achieves high rates of molecular response in newly diagnosed CML-CP. Serum creatinine increases were generally mild, occurred early during treatment, and subsequently stabilized, with no consistent association observed with two groups, MMR rate, or the extent of BCR::ABL1 reduction. These findings support the safety profile of flumatinib with respect to renal function and underscore the importance of routine renal monitoring during therapy.
DISCLOSURES
Qiang WANG, MD: No relevant conflicts of interest to declare.